July 2024—Progentec Diagnostics proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available. The AiSLE DX lupus disease activity index and AiSLE DX lupus flare risk index tests are the result of a collaboration with Mayo Clinic Laboratories and are now accessible to all clients of Mayo Clinic Labs.
The two tests are for lupus disease management and based on proprietary indices computed based on advanced algorithms. The AiSLE DX lupus disease activity index is useful in identifying if patients have active disease and includes 10 biomarkers. Results from this test can also be used to help determine the frequency of care assessment, guide disease management, and evaluate if an early intervention for treatment is needed. The AiSLE DX lupus flare risk index uses 11 biomarkers to determine, up to 12 weeks in advance, the risk of onset of a lupus flare.
Mayo Clinic Laboratories, 507-266-5700
Progentec Diagnostics, 833-587-8739